Abametapir

Abametapir, sold under the brand name Xeglyze, is a medication used for the treatment of head lice infestation in people six months of age and older.[1][2]

Abametapir

Clinical data
Trade names	Xeglyze
Other names	Ha44
AHFS/Drugs.com	Xeglyze
License data	US DailyMed: Abametapir
Routes of administration	Topical
Drug class	Pediculicide, Metalloproteinase inhibitor
ATC code	None
Legal status
Legal status	US: ℞-only [1]
Identifiers
IUPAC name 5,5'-dimethyl-2,2'-bipyridine
CAS Number	1762-34-1
PubChem CID	15664
DrugBank	DB11932
ChemSpider	14899
UNII	6UO390AMFB
KEGG	D10687
ChEMBL	ChEMBL2205807
PDB ligand	EI3 (PDBe, RCSB PDB)
Chemical and physical data
Formula	C12H12N2
Molar mass	184.242 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CC1=CN=C(C=C1)C2=NC=C(C=C2)C
InChI InChI=1S/C12H12N2/c1-9-3-5-11(13-7-9)12-6-4-10(2)8-14-12/h3-8H,1-2H3 Key:PTRATZCAGVBFIQ-UHFFFAOYSA-N

The most common side effects include skin redness, rash, skin burning sensation, skin inflammation, vomiting, eye irritation, skin itching, and hair color changes.[2]

Abametapir is a metalloproteinase inhibitor.[1] Abametapir was approved for medical use in the United States in July 2020.[1][3]

Medical uses

Abametapir is indicated for the topical treatment of head lice infestation in people six months of age and older.[1][2]

History

The U.S. Food and Drug Administration (FDA) approved abametapir based on evidence from two identical clinical trials of 699 participants with head lice.[2] The trials were conducted at fourteen sites in the United States.[2]

The benefit and side effects of abametapir were evaluated in two clinical trials that enrolled participants with head lice who were at least six months old.[2]

About half of all enrolled participants was randomly assigned to abametapir and the other half to placebo.[2] Abametapir lotion or placebo lotion were applied once as a ten-minute treatment to infested hair.[2] The benefit of abametapir in comparison to placebo was assessed after 1, 7 and 14 days by comparing the counts of participants in each group who were free of live lice.[2]

References

1. "Xeglyze (abametapir) lotion, for topical use" (PDF). U.S. Food and Drug Administration (FDA). Dr. Reddy's Laboratories. Inc. Retrieved 25 July 2020.
2. "Drug Trial Snapshot: Xeglyze". U.S. Food and Drug Administration (FDA). 24 July 2020. Retrieved 6 August 2020. This article incorporates text from this source, which is in the public domain.
3. "Abametapir: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 July 2020.

Further reading

• Bowles VM, VanLuvanee LJ, Alsop H, Hazan L, Shepherd K, Sidgiddi S, et al. (September 2018). "Clinical studies evaluating abametapir lotion, 0.74%, for the treatment of head louse infestation". Pediatr Dermatol. 35 (5): 616–621. doi:10.1111/pde.13612. PMC 6175393. PMID 29999197.

External links

• "Abametapir". Drug Information Portal. U.S. National Library of Medicine.